$DMAC
DiaMedica Therapeutics Inc. Stock $dmac

$dmac Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000143774924025198 Filed on August 07, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.900M	$1.710M
YoY Change	0.53%	-22.2%
% of Gross Profit
Research & Development	$4.983M	$3.928M
YoY Change	52.29%	54.46%
% of Gross Profit
Depreciation & Amortization	$10.00K	$10.00K
YoY Change	0.0%	42.86%
% of Gross Profit
Operating Expenses	$4.983M	$3.928M
YoY Change	52.29%	54.46%
Operating Profit	-$6.883M	-$5.638M
YoY Change	33.47%	18.92%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$616.0K	$526.0K
YoY Change	-11.11%	94.1%
Pretax Income	-$6.267M	-$5.112M
YoY Change	40.39%	14.36%
Income Tax	$7.000K	$7.000K
% Of Pretax Income
Net Earnings	-$6.274M	-$5.119M
YoY Change	40.33%	14.34%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.15	-$0.13
Diluted Earnings Per Share	-$0.15	-$0.13
COMMON SHARES
Basic Shares Outstanding	42.75M	37.96M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$50.20M	$54.06M
YoY Change	8.02%	33.91%
Cash & Equivalents	$4.134M	$14.07M
Short-Term Investments	$46.06M	$39.99M
Other Short-Term Assets	$280.0K	$568.0K
YoY Change	-75.0%	-15.85%
Inventory
Prepaid Expenses
Receivables	$290.0K	$391.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$50.77M	$55.01M
YoY Change	6.02%	33.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$151.0K	$152.0K
YoY Change	11.85%	14.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.308M	$1.308M
YoY Change
Total Long-Term Assets	$1.757M	$1.777M
YoY Change	-82.86%	-91.46%
TOTAL ASSETS
Total Short-Term Assets	$50.77M	$55.01M
Total Long-Term Assets	$1.757M	$1.777M
Total Assets	$52.52M	$56.79M
YoY Change	-9.66%	-8.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.171M	$759.0K
YoY Change	35.69%	-11.33%
Accrued Expenses	$3.024M	$2.229M
YoY Change	146.45%	120.47%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$14.00K	$15.00K
YoY Change		400.0%
Total Short-Term Liabilities	$4.297M	$3.088M
YoY Change	98.02%	58.68%
LONG-TERM LIABILITIES
Long-Term Debt	$249.0K	$16.00K
YoY Change		300.0%
Other Long-Term Liabilities	$14.00K	$272.0K
YoY Change	-95.88%	-23.81%
Total Long-Term Liabilities	$263.0K	$288.0K
YoY Change	-22.65%	-20.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.297M	$3.088M
Total Long-Term Liabilities	$263.0K	$288.0K
Total Liabilities	$4.560M	$3.376M
YoY Change	81.67%	46.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$132.1M	-$125.8M
YoY Change	19.66%	18.79%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$48.00M	$53.40M
YoY Change
Total Liabilities & Shareholders Equity	$52.52M	$56.79M
YoY Change	-9.66%	-8.48%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$6.274M	-$5.119M
YoY Change	40.33%	14.34%
Depreciation, Depletion And Amortization	$10.00K	$10.00K
YoY Change	0.0%	42.86%
Cash From Operating Activities	-$4.470M	-$4.519M
YoY Change	-6.88%	-10.16%
INVESTING ACTIVITIES
Capital Expenditures	$9.000K	$0.00
YoY Change	-10.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$5.576M	$4.736M
YoY Change	-560.83%	-116.84%
Cash From Investing Activities	-$5.585M	$4.736M
YoY Change	-565.42%	-116.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	123.0K	11.75M
YoY Change	-1330.0%	-68.11%
NET CHANGE
Cash From Operating Activities	-4.470M	-4.519M
Cash From Investing Activities	-5.585M	4.736M
Cash From Financing Activities	123.0K	11.75M
Net Change In Cash	-9.932M	11.97M
YoY Change	175.12%	224.19%
FREE CASH FLOW
Cash From Operating Activities	-$4.470M	-$4.519M
Capital Expenditures	$9.000K	$0.00
Free Cash Flow	-$4.479M	-$4.519M
YoY Change	-6.88%	-10.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	568000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	411000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	369000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37958000
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	391000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10270000	usd
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37958000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001401040
	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	31827000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	422000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	45000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5272000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	27022000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1400000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	36852000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	380000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-34000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4477000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	59743000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9749000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	931000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	802000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	648000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	432000	usd
	dmac	Noncash Lease Expense NoncashLeaseExpense	37000	usd
	dmac	Noncash Lease Expense NoncashLeaseExpense	34000	usd
	us-gaap	Depreciation Depreciation	18000	usd
	us-gaap	Depreciation Depreciation	14000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	106000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	156000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	424000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	1308000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-167000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	122000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	413000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-380000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11172000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10119000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	18047000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	52743000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	27000000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	27135000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8944000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25619000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11747000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	36852000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	3000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	3000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11751000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	36849000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9523000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1111000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4543000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4728000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14066000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5839000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	30000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	14000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	20000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-125800000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10300000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11200000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	54100000	usd
CY2024Q2	dmac	Working Capital WorkingCapital	51900000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	53400000	usd
	dmac	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	11700000	usd
CY2024Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent	387000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	298000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	250000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	231000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	98000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	100000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	152000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	131000	usd
CY2024Q2	dmac	Accrued Clinical Study Costs Current AccruedClinicalStudyCostsCurrent	903000	usd
CY2023Q4	dmac	Accrued Clinical Study Costs Current AccruedClinicalStudyCostsCurrent	258000	usd
CY2024Q2	dmac	Accrued Research And Professional Fees Current AccruedResearchAndProfessionalFeesCurrent	688000	usd
CY2023Q4	dmac	Accrued Research And Professional Fees Current AccruedResearchAndProfessionalFeesCurrent	632000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	473000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	766000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	155000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	98000	usd
CY2024Q2	dmac	Accrued Taxes And Other Liabilities Current AccruedTaxesAndOtherLiabilitiesCurrent	10000	usd
CY2023Q4	dmac	Accrued Taxes And Other Liabilities Current AccruedTaxesAndOtherLiabilitiesCurrent	23000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2229000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1777000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	52000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	52000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	38000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	40000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	55000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	113000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	116000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	119000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	413000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	56000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	357000	usd
	dmac	Stock Issued During Period Shares Restricted Stock Units StockIssuedDuringPeriodSharesRestrictedStockUnits	11832
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2750
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000	usd
	dmac	Stock Issued During Period Shares Settlement Of Deferred Stock Units StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits	17621
	dmac	Stock Issued During Period Shares Restricted Stock Units StockIssuedDuringPeriodSharesRestrictedStockUnits	8578
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8367551
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-5119000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4477000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10270000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9749000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38068378
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27312008
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38013189
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26882858
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	443000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	380000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	931000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	802000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2750
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.45
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4859271
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.31
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1037000	usd
CY2024Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	4859271
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y6M
CY2024Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	3.31
CY2024Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	2199459
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P5Y10M24D

Files In Submission

Name	View Source	Status
0001437749-24-025198-index-headers.html	Edgar Link	pending
0001437749-24-025198-index.html	Edgar Link	pending
0001437749-24-025198.txt	Edgar Link	pending
0001437749-24-025198-xbrl.zip	Edgar Link	pending
dmac-20240630.xsd	Edgar Link	pending
dmtp20240630_10q.htm	Edgar Link	pending
dmtp20240630_10qimg001.jpg	Edgar Link	pending
ex_707476.htm	Edgar Link	pending
ex_707477.htm	Edgar Link	pending
ex_707478.htm	Edgar Link	pending
ex_707479.htm	Edgar Link	pending
dmac-20240630_cal.xml	Edgar Link	unprocessable
dmac-20240630_def.xml	Edgar Link	unprocessable
dmac-20240630_lab.xml	Edgar Link	unprocessable
dmac-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
dmtp20240630_10q_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DMAC
DiaMedica Therapeutics Inc. Stock $dmac

2024 Q3 Form 10-Q Financial Statement

#000143774924025198 Filed on August 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DMAC DiaMedica Therapeutics Inc. Stock $dmac

2024 Q3 Form 10-Q Financial Statement

#000143774924025198 Filed on August 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DMAC
DiaMedica Therapeutics Inc. Stock $dmac